Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
News Menu

News

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

GlobeNewswire - Press Release

All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Follow us on Google News Follow us on Google News

Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder

Regulatory milestone enables Company to raise up to $50 million through second closing of private placement announced September 2025

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

Related Symbols

Symbol Last Chg %Chg
CAMP 4.15 +0.01 +0.24%
Camp4 Therapeutics Corp

Most Popular News

A photo of CEO Jensen Huang in front of the Nvidia logo by FotoField via Shutterstock 1
Nvidia Reports $7.8 Billion in Q2 Gains on Equity Portfolio That Includes SpaceX, Intel, CoreWeave, and More
Ai chip by Quality Stock Arts via Shutterstock 2
Why Corning Stock Can Make a Comeback Here
A concept image for blue-chip stocks by zimmytws via Shutterstock 3
Unusual Options Activity: NFLX, HONA, and MSFT Lead the Way With These 3 Options Strategies
A close-up of the Broadcom logo on a smartphone by Timon via Adobe Stock 4
Spicy Stocks: Why BNP Thinks Jalapeño Could Benefit Broadcom Stock
Desk setup looking at stocks by LanaStock via iStock 5
Sofi Stock Is Failing to Break $20 This Year, but You Shouldn’t Give Up Yet
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.